{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T12:33:28Z","timestamp":1786624408103,"version":"build-2736575974"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The diagnostic criteria for TAFRO syndrome exclude autoimmune diseases, and they have been considered to be mutually independent. However, several cases of autoimmune diseases with TAFRO signs have been reported in recent years. Also, similarities in cytokine profiles in COVID-19 and TAFRO syndrome have been previously reported. Our patient, a 53-year-old Japanese man, was diagnosed with COVID-19 and had a persistent fever. Two weeks later, pain, numbness, and oedema appeared, mainly in the right lower leg but gradually spreading to the distal extremities. Subsequently, purpura appeared on his forearms and lower legs, and 10\u00a0weeks after the COVID-19 diagnosis he presented to our hospital. On admission, in addition to fever, polyangiitis, and purpura of the extremities, he had splenomegaly, lymphadenopathy, and anasarca. Skin and renal histopathology revealed fibrinoid necrotising vasculitis of small and medium-sized arteries. In addition, his platelet count was low, Alkaline phosphatase (ALP) was elevated, and there was anasarca, fever, and renal failure. A diagnosis of polyarteritis nodosa with TAFRO signs was made. On the 20th day of admission, high-dose glucocorticoids and high-dose intravenous cyclophosphamide were started. The platelet count initially improved, with gradual improvement of vasculitis and symptoms of fever, purpura, and neuropathy. However, there was another decrease in platelets, progression of renal dysfunction, and worsening of fluid retention. Tocilizumab was added, but the disease could not be controlled, and on the 51st day, necrotising fasciitis developed and the patient died. This case suggests that COVID-19, TAFRO syndrome, and vasculitis may be interrelated in their pathogeneses.<\/jats:p>","DOI":"10.1093\/mrcr\/rxaf075","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T12:26:29Z","timestamp":1763382389000},"source":"Crossref","is-referenced-by-count":0,"title":["Polyarteritis nodosa presenting with TAFRO signs following COVID-19 infection: case report"],"prefix":"10.1093","volume":"10","author":[{"given":"Rina","family":"Ishigame","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Iwate Prefectural Chubu Hospital , Iwate ,","place":["Japan"]},{"name":"Department of Rheumatology and Clinical Immunology, Wakayama Medical University , Wakayama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2076-1603","authenticated-orcid":false,"given":"Shigeru","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Wakayama Medical University , Wakayama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayoko","family":"Tabata","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wakayama Medical University , Wakayama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromitsu","family":"Kita","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Wakayama Medical University , Wakayama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Wakayama Medical University , Wakayama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Nakatsuka","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wakayama Medical University , Wakayama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Tabata","sequence":"additional","affiliation":[{"name":"Department of Hematology, Wakayama Medical University , Wakayama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuta","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Department of Human Pathology, Wakayama Medical University , Wakayama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Jinnin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wakayama Medical University , Wakayama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichi","family":"Araki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Wakayama Medical University , Wakayama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Wakayama Medical University , Wakayama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"2026081307263557700_ref1","doi-asserted-by":"crossref","first-page":"103137","DOI":"10.1016\/j.autrev.2022.103137","article-title":"TAFRO syndrome: a severe manifestation of Sj\u00f6gren's syndrome? A systematic review","volume":"21","author":"Grange","year":"2022","journal-title":"Autoimmun Rev"},{"issue":"12","key":"2026081307263557700_ref2","first-page":"12175","article-title":"A case of repeated TAFRO syndrome-like symptoms and retroperitoneal hemorrhage in a patient with Sj\u00f6gren syndrome","volume":"19","author":"Ohta","year":"2020","journal-title":"Cureus"},{"key":"2026081307263557700_ref3","doi-asserted-by":"crossref","first-page":"9220","DOI":"10.1097\/MD.0000000000009220","article-title":"Sj\u00f6gren's syndrome manifesting as clinicopathological features of TAFRO syndrome","volume":"96","author":"Fujimoto","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"2026081307263557700_ref4","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1002\/ccr3.2502","article-title":"Multicentric Castleman disease with TAFRO syndrome and Sj\u00f6gren's","volume":"7","author":"Li","year":"2019","journal-title":"Clin Case Rep"},{"key":"2026081307263557700_ref5","first-page":"688","article-title":"Systemic lupus erythematosus with marked eosinophilia and clinical features mimicking TAFRO syndrome","volume":"59","author":"Tokunaga","year":"2018","journal-title":"Rinsho Ketsueki"},{"key":"2026081307263557700_ref6","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1177\/0961203317725589","article-title":"Characterization of patients with systemic lupus erythematosus who meet the diagnostic criteria for TAFRO syndrome","volume":"27","author":"Hasegawa","year":"2018","journal-title":"Lupus"},{"key":"2026081307263557700_ref7","doi-asserted-by":"crossref","first-page":"22793","DOI":"10.1097\/MD.0000000000022793","article-title":"Development of severe thrombocytopenia with TAFRO syndrome-like features in a patient with rheumatoid arthritis treated with a Janus kinase inhibitor","volume":"99","author":"Kadoba","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"2026081307263557700_ref8","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jiac.2022.04.005","article-title":"TAFRO syndrome with a fatal clinical course following BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccination: a case report","volume":"28","author":"Yamada","year":"2022","journal-title":"J Infect Chemother"},{"key":"2026081307263557700_ref9","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s12185-023-03589-9","article-title":"Severe systemic inflammation mimicking TAFRO syndrome following COVID-19","volume":"118","author":"Tane","year":"2023","journal-title":"Int J Hematol"},{"key":"2026081307263557700_ref10","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.revmed.2020.10.384","article-title":"TAFRO syndrome and cutaneous necrotizing vasculitis","volume":"42","author":"Maquet","year":"2021","journal-title":"Rev Med Interne"},{"key":"2026081307263557700_ref11","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/art.1780330805","article-title":"The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa","volume":"33","author":"Lightfoot","year":"1990","journal-title":"Arthritis Rheum"},{"key":"2026081307263557700_ref12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12185-019-02780-1","article-title":"Japanese TAFRO Syndrome Research Team. 2019 updated diagnostic criteria and disease severity classification for TAFRO syndrome","volume":"111","author":"Masaki","year":"2020","journal-title":"Int J Hematol"},{"key":"2026081307263557700_ref13","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.3390\/biomedicines12061287","article-title":"TAFRO syndrome and COVID-19","volume":"12","author":"Tane","year":"2024","journal-title":"Biomedicines"},{"issue":"6","key":"2026081307263557700_ref14","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.3390\/biomedicines12061277","article-title":"TAFRO syndrome: guidance for managing patients presenting thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly","volume":"12","author":"Miura","year":"2024","journal-title":"Biomedicines"},{"issue":"6","key":"2026081307263557700_ref15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41584-021-00608-z","article-title":"Systemic and organ-specific immune-related manifestations of COVID-19","volume":"17","author":"Ramos-Casals","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"2026081307263557700_ref16","doi-asserted-by":"crossref","first-page":"100158","DOI":"10.1016\/j.clinpr.2022.100158","article-title":"Severe coronavirus disease 2019 in a patient with TAFRO syndrome: a case report","volume":"16","author":"Oshima","year":"2022","journal-title":"Clin Infect Pract"},{"key":"2026081307263557700_ref17","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/hon.3075","article-title":"TAFRO syndrome: a disease that known is half cured","volume":"41","author":"Chen","year":"2023","journal-title":"Hematol Oncol"},{"key":"2026081307263557700_ref18","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/ajh.24242","article-title":"Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease","volume":"91","author":"Iwaki","year":"2016","journal-title":"Am J Hematol"},{"key":"2026081307263557700_ref19","doi-asserted-by":"crossref","first-page":"42316","DOI":"10.1038\/srep42316","article-title":"Elevated serum interferon \u03b3-induced protein 10 kDa is associated with TAFRO syndrome","volume":"7","author":"Iwaki","year":"2017","journal-title":"Sci Rep"},{"key":"2026081307263557700_ref20","doi-asserted-by":"crossref","first-page":"1170012","DOI":"10.3389\/fimmu.2023.1170012","article-title":"Characterisation of the pro-inflammatory cytokine signature in severe COVID-19","volume":"14","author":"Hawerkamp","year":"2023","journal-title":"Front Immunol"},{"key":"2026081307263557700_ref21","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3390\/medicina58020144","article-title":"Cytokine storm in COVID-19: immunopathogenesis and therapy","volume":"58","author":"Zanza","year":"2022","journal-title":"Medicina (Kaunas)"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxaf075\/65408060\/rxaf075.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/10\/1\/rxaf075\/65408060\/rxaf075.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/10\/1\/rxaf075\/65408060\/rxaf075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T11:57:05Z","timestamp":1786622225000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/doi\/10.1093\/mrcr\/rxaf075\/8329241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxaf075","relation":{},"ISSN":["2472-5625"],"issn-type":[{"value":"2472-5625","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2025,11,20]]},"article-number":"rxaf075"}}